Selective Serotonin Reuptake Inhibitors: Pharmacology, Administration, and Side Effects
Introduction and Indications
Selective serotonin reuptake inhibitors (SSRIs) are a class of medications frequently utilized as first-line antidepressants due to their established efficacy, favorable tolerability, and general safety in the event of an overdose. The primary SSRIs discussed include:
Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Beyond unipolar depression, SSRIs are indicated for a spectrum of conditions:
Anxiety disorders
Eating disorders
Menopausal hot flashes
Obsessive-compulsive and related disorders
Posttraumatic stress disorder (PTSD)
Premature ejaculation
Premenstrual dysphoric disorder (PMDD)
Somatic symptom disorder
Pharmacology: Structure and Dynamics
Chemical Structure SSRIs vary significantly in chemical structure. Paroxetine and sertraline exist as single isomers. In contrast, citalopram and fluoxetine are racemic mixtures consisting of two superimposable mirror-image stereoisomers. Escitalopram is specifically the -isomer of citalopram (-citalopram) and is the stereoisomer that more potently inhibits serotonin reuptake.
Pharmacodynamics The primary mechanism involves increasing serotonergic activity by selectively inhibiting the presynaptic serotonin reuptake pump. Serotonin, known as -hydroxytryptamine or , is an indoleamine neurotransmitter released from the brainstem raphe nuclei. Brain neurotransmission involves at least different types of pre- and postsynaptic serotonin receptors.
Key dynamic features include:
Reuptake Inhibition: SSRIs decrease the action of the reuptake pump by as much as , increasing the duration serotonin remains in the synapse and increasing postsynaptic receptor occupancy.
Target Selectivity: They have relatively little affinity for other receptors (alpha-adrenergic, histaminic, or cholinergic), which accounts for their benign side effect profile relative to older antidepressants. Paroxetine is a minor exception, showing weak antagonism for cholinergic receptors.
Downstream Effects: Therapeutic response is not solely due to reuptake inhibition, which occurs shortly after administration. Full clinical effect often requires to weeks (or more), likely involving downstream changes such as increased production of neuroprotective proteins (e.g., brain-derived neurotrophic factor, Bc1-2) and modification of serotonergic receptor subtypes over weeks of treatment.
Pharmacokinetics and Drug-Drug Interactions
Absorption and Distribution SSRIs are well-absorbed in the gastrointestinal tract, reaching peak plasma levels within to hours. They are lipophilic, protein-bound, and widely distributed throughout the body including the brain. Food generally does not affect absorption, with the exception of sertraline, which is absorbed more rapidly when taken with food.
Metabolism and Elimination Metabolism occurs primarily in the liver. All SSRIs except fluvoxamine produce pharmacologically active metabolites. Fluoxetine is unique as it yields norfluoxetine, which potently inhibits serotonin reuptake and possesses antidepressant activity.
Elimination half-lives are as follows:
Citalopram: to
Escitalopram: to
Fluoxetine: to (Active metabolite norfluoxetine: to )
Fluvoxamine:
Paroxetine:
Sertraline:
Hepatic Enzyme Inhibition (CYP450) SSRIs vary in their inhibition of cytochrome P450 enzymes, which can lead to significant drug-drug interactions:
Fluoxetine: Potent inhibitor of CYP2D6; moderate inhibitor of CYP2C19.
Fluvoxamine: Potent inhibitor of CYP1A2; moderate inhibitor of CYP2C19.
Paroxetine: Potent inhibitor of CYP2D6.
Citalopram and Escitalopram: Show the least inhibition of liver enzymes and are preferred when drug-drug interactions are a primary concern.
Notable Clinical Interactions
Tamoxifen: Fluoxetine and paroxetine (CYP2D6 inhibitors) can interfere with the conversion of the prodrug tamoxifen to its active metabolite for breast cancer treatment. Use of alternative antidepressants is preferred.
Prodrug Opioids: CYP2D6 inhibitors can prevent the conversion of codeine, hydrocodone, and tramadol into their active forms (e.g., morphine). A 9-year study showed worse postoperative pain control in patients taking SSRIs with prodrug opioids vs. non-prodrug opioids like morphine or fentanyl.
Serotonin Syndrome: Co-administration with other serotonergic agents (e.g., MAOIs, lithium, SNRIs, St. John's wort) increases the risk of serotonin syndrome.
Clinical Administration: Dosing and Response
General Principles SSRIs are contraindicated in patients with hypersensitivity or those who have taken a monoamine oxidase inhibitor (MAOI) within the previous . Clinicians should discuss side effects, response time, and the risks of abrupt discontinuation (discontinuation syndrome: dysphoria, dizziness, GI distress, fatigue).
Equipotent Initial Dosing for Depression
Citalopram: (Max in most; in patients or with hepatic impairment).
Escitalopram: (Max ).
Fluoxetine: (Max ).
Fluvoxamine: Starting ; maintain at to (Divided doses if ).
Paroxetine: (Max ).
Sertraline: (Max ; doses up to have been used).
Titration and Timing
Doses are generally taken once daily, usually in the morning to minimize insomnia.
Adjustment: Evaluate response for to at the minimum therapeutic dose before adjusting. Increases typically occur every to .
Patients with comorbid anxiety may require starting at half the usual dose to improve tolerability.
Response Time Statistics
STAR*D Study: In outpatients, mean time to response for citalopram was ;
Fluoxetine Study: In outpatients, the cumulative probability of response was at week 2, at week 4, and at week 6.
Medical Tests and Plasma Levels
No mandatory medical tests are required prior to starting an SSRI. Serum concentrations are not standard practice but may be useful for:
Validating safety when starting an MAOI (waiting elimination half-lives is the standard alternative).
Monitoring rapid metabolizers, treatment-resistant cases, or specific populations (children, elderly, pregnant, or patients with hepatic disease).
Reference Ranges for Plasma Levels
Citalopram: to
Escitalopram: to
Fluoxetine + Norfluoxetine: to
Fluvoxamine: to
Paroxetine: to
Sertraline: to
Safety Profile: Adverse Effects and Warnings
Commonly Reported Side Effects
Nausea: Most common; mitigated by starting at low doses and taking with food. More frequent with paroxetine and fluvoxamine.
Sexual Dysfunction: High incidence (addressed in separate literature).
Weight Change: Short-term effects vary by medication ( to ); paroxetine is most associated with weight gain.
CNS Effects: Insomnia, somnolence, headache, tremor, activation (fluoxetine/sertraline), and sedation (paroxetine/fluvoxamine).
Suicide Risk Evidence on whether antidepressants increase suicidality is inconclusive. Age-specific risk nuances suggest:
Age to : Slight increase in risk.
Age to : No effect.
Age : Potentially lowers risk.
Cardiac Effects (QTc Prolongation) Citalopram causes dose-dependent prolongation of the corrected QT interval, potentially leading to Torsade de Pointes.
FDA Finding for Citalopram: caused prolongation; caused .
FDA Warning: Max dose ; limit to if age or hepatic impairment. Avoid in those with congenital long QT, bradycardia, or hypokalemia.
Escitalopram: At , QTc increase was . FDA did not issue a mandatory warning, though some reports suggest caution.
Safest for Heart Disease: Sertraline and fluoxetine are often cited as having the lowest risk of QTc prolongation.
Bleeding Risk SSRIs inhibit the serotonin transporter in platelets, reducing platelet aggregation.
Observational risk: Odds ratio () for serious bleeding is .
GI Bleeding: increases to in SSRI users and as high as to when combined with NSAIDs.
Management: PPIs are sometimes prescribed when SSRIs are used with NSAIDs to reduce GI risk.
Hyponatremia (SIADH) Primarily occurs in adults , especially within the first of treatment ().
Comparison of incidence rate ratios (): Citalopram (), Fluoxetine (), Paroxetine (), Sertraline ().
Serotonin Syndrome and Overdose
Serotonin Syndrome A potentially lethal overstimulation of serotonin receptors.
Symptoms: Anxiety, delirium, diaphoresis, tachycardia, hyperthermia, tremor, hyperreflexia, and muscle rigidity.
Management: Discontinue all serotonergic agents. Supportive care with oxygen and IV fluids. Use benzodiazepines (lorazepam to IV) for agitation and neuromuscular symptoms. If benzodiazepines fail, administer cyproheptadine ( initial adult dose).
Overdose Management SSRI overdoses are rarely fatal unless involving extremely large quantities or coingestion of other substances.
Symptoms: Drowsiness, tremor, and vomiting.
Citalopram Toxicity: Citalopram is considered the most lethal SSRI in overdose (Poison Center data shows mortality risk higher than paroxetine and higher than fluoxetine/sertraline due to QTc effects).
Treatment Protocol: Activated charcoal (; standard for adults). Treat seizures with lorazepam. Treat prolonged QRS () with sodium bicarbonate ( to IV). Treat Torsades de Pointes with magnesium sulfate ( IV).